Page 6,723«..1020..6,7226,7236,7246,725..6,7306,740..»

San Antonio's Cisneros opens up about cancer battle

Posted: Published on June 19th, 2012

SAN ANTONIO - Henry Cisneros still talks about housing and urban development with passion, about the future of cities and the ways in which immigrant communities can help the country thrive. He still talks politics and remains involved with President Barack Obama's re-election campaign. But these days, the former San Antonio mayor and U.S. housing secretary also talks a lot about RADS, or radiation absorbed dosages, in the same energetic, enthusiastic tone, as if explaining a new pension fund in which his company is investing. It's almost like he's not talking about cancer. His cancer. Cisneros, who turned 65 last week and just published a book about aging, is fighting prostate cancer, among the most common diseases among men. This year, nearly 242,000 cases will be diagnosed and more than 28,000 men will die, according to the American Cancer Society. Prostate cancer is tough for men to talk about, especially in public, and perhaps more so for a man who has spent so much of his life in the public eye - for better and worse. If he's squeamish or uncomfortable, it doesn't show. He laughs about what fellow patients and survivors have told him about their journeys and how … Continue reading →

Posted in Impotency | Comments Off on San Antonio's Cisneros opens up about cancer battle

Study of Cell Therapeutics’ Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic …

Posted: Published on June 19th, 2012

SEATTLE, June 18, 2012 /PRNewswire/ --Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that the University of Washington ("UW") has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome ("MDS"). Drs. John Pagel and Elihu Estey, from the University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, are leading the study. "This is the first study to examine the effects of tosedostat in combination with either cytarabine or decitabine as a first-line therapy. The study will evaluate how well patients tolerate these combinations, and their effectiveness. Given that there have been no major advances in treatment of elderly patients with AML, and the results of a previous study of tosedostat by itself in relapsed or refractory patients with AML or MDS showed promising anti-leukemic effects and acceptable tolerability, we are hopeful that this study will demonstrate that tosedostat increases the limited efficacy of these commonly used anti-leukemic agents," Dr. Estey said. The study's primary objectives are to determine the four-month survival and complete response ("CR") rates of tosedostat in combination with either … Continue reading →

Posted in Cell Medicine | Comments Off on Study of Cell Therapeutics’ Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic …

Study of Cell Therapeutics' Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic …

Posted: Published on June 19th, 2012

SEATTLE, June 18, 2012 /PRNewswire/ --Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that the University of Washington ("UW") has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome ("MDS"). Drs. John Pagel and Elihu Estey, from the University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, are leading the study. "This is the first study to examine the effects of tosedostat in combination with either cytarabine or decitabine as a first-line therapy. The study will evaluate how well patients tolerate these combinations, and their effectiveness. Given that there have been no major advances in treatment of elderly patients with AML, and the results of a previous study of tosedostat by itself in relapsed or refractory patients with AML or MDS showed promising anti-leukemic effects and acceptable tolerability, we are hopeful that this study will demonstrate that tosedostat increases the limited efficacy of these commonly used anti-leukemic agents," Dr. Estey said. The study's primary objectives are to determine the four-month survival and complete response ("CR") rates of tosedostat in combination with either … Continue reading →

Posted in Cell Medicine | Comments Off on Study of Cell Therapeutics' Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic …

Chicago woman cured of sickle cell disease

Posted: Published on June 19th, 2012

ScienceDaily (June 18, 2012) Chicagoan Ieshea Thomas is the first Midwest patient to receive a successful stem cell transplant to cure her sickle cell disease without chemotherapy in preparation for the transplant. University of Illinois Hospital & Health Sciences System physicians performed the procedure using medication to suppress her immune system and one small dose of total body radiation right before the transplant. The transplant technique is relatively uncommon and is a much more tolerable treatment for patients with aggressive sickle cell disease who often have underlying organ disease and other complications, says Dr. Damiano Rondelli, professor of medicine at UIC, who performed Thomas's transplant. The procedure initially allows a patient's own bone marrow to coexist with that of the donor. Since the patient's bone marrow is not completely destroyed by chemotherapy or radiation prior to transplant, part of the immune defense survives, lessening the risk of infection. The goal is for the transplanted stem cells to gradually take over the bone marrow's role to produce red blood cells -- normal, healthy ones. Thomas, 33, had her first sickle cell crisis when she was just 8 months old. Her disease became progressively worse as an adult, particularly after the birth … Continue reading →

Posted in Cell Medicine | Comments Off on Chicago woman cured of sickle cell disease

uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy

Posted: Published on June 19th, 2012

AMSTERDAM, The Netherlands, June 18, 2012 /PRNewswire/ -- uniQure, a leader in the field of human gene therapy, announced today the extension of its collaboration with Protein Sciences Corporation ("Protein Sciences") for the exclusive use of Protein Sciences' expresSF+ (SF+) insect cell line in uniQure's AAV gene therapy programs for three specific disease indications. uniQure has the option to extend this exclusivity further into additional indications in the future. "This agreement strengthens uniQure's gene therapy platform and further demonstrates the quality of the cell line developed by Protein Sciences." said Joern Aldag, Chief Executive of uniQure. "Protein Sciences' cell line license agreement with Merck made earlier this year and the anticipated approval of its influenza vaccine FluBlok implies SF+ technology will hold a prominent place in the manufacture of biologics." The SF+ cell line developed by Protein Sciences is an integral component of uniQure's validated, world leading manufacturing platform. uniQure believes that this platform is the only commercially-scalable platform available for manufacturing AAV gene therapy products. Financial terms were not disclosed. About uniQure uniQure is a world leader in the development ofhuman gene based therapies.uniQure has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent … Continue reading →

Posted in Cell Therapy | Comments Off on uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy

Sistemic to Moderate Regenerative Medicine Panel at 2012 Bio International Convention

Posted: Published on June 19th, 2012

BOSTON--(BUSINESS WIRE)-- Sistemic Ltd., a leading provider of microRNA-based problem-solving services and kit-based products to the Cell Therapy community, announced today that chairman and CEO Jim Reid is moderating a panel discussion at the 2012 Bio International Convention on Wednesday, June 20, in Boston. Featuring leaders from the regenerative medicine space, the panel is titled Stem Cell Therapies Fact or Fiction, and will share the lessons learned to-date from Scottish, European and American perspectives on the path to successfulcommercialization of stem cell therapies. Jim Reid, Sistemic CEO, commented, "Sistemic is very active in the CellTherapyarena and aremembersof Alliance for Advanced Therapies (AAT) and the Alliance for Regenerative Medicine (ARM). We see the ability to raise this topic at the leading world event, BIO 2012, as animportantstep on the path to commercialization of these products which will be transformational in healthcare, and bring hope and cures to many people around the globe." More information on the panel at BIO 2012: What: Panel Discussion Featuring Leaders in the Regenerative Medicine Space When: Wednesday, June 20, 3:00PM EDT Where: Boston Convention Center, Room 254A Who: Leaders of the Regenerative Medicine space: Panel objectives include evaluating lessons learned and best practice including from the … Continue reading →

Posted in Cell Therapy | Comments Off on Sistemic to Moderate Regenerative Medicine Panel at 2012 Bio International Convention

Propecia Still Being Given Despite the Known Risks

Posted: Published on June 19th, 2012

Attorney (866) 735-1102 Ext 305 The hair growth drug, Propecia, was first approved in 1997 by the Food and Drug Administration (FDA). When the drug was first introduced into the market, a number of researchers and doctors expressed concerns about Propecias severe side effects. According to John Peige of the Baltimore Courts Examiner, one of these doctors who expressed serious concerns about Propecia was well-known hair-restoration expert L. Lee Bosley. Dr. Bosley publicly denounced Propecia, saying that the drug had serious side effects and health concerns. Dr. Bosley is quoted in Business Wire headlined, Supposed Miracle Baldness Cure Creates Serious Health Concerns Among Hair Restoration Professionals, saying: "The FDA has just approved a drug that has the capability to impair male sexual performance, creating the inability to achieve an erection [and] decreases libido... The potential side effects, especially the long-term side effects of the drug, should be the overriding concerns to both the users and the manufacturer." It was only a few years later when Dr. Bosley allowed his doctors to recommend Propecia to patients. Even while the Bosley Medical group knew of the dangerous side effects Propecia had, they did not warn patients who were prescribed this drug. The … Continue reading →

Posted in Drug Side Effects | Comments Off on Propecia Still Being Given Despite the Known Risks

Hometownstations.com-WLIO- Lima, OH News Weather SportsFDA focuses on toxic side effects with Onyx drug

Posted: Published on June 19th, 2012

By MATTHEW PERRONE AP Health Writer WASHINGTON (AP) - The toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh its benefits for patients with a type of blood cancer, federal health regulators said Monday. The Food and Drug Administration warned that patients in a company study of the drug had a high rate of heart and lung side effects, some which were fatal. The FDA posted its review of carfilzomib online ahead of a meeting Wednesday, where its panel of cancer experts will recommend whether the drug should be approved. Despite the negative tone of the review, some analysts said they expect the FDA's panel of outside experts to take a more favorable view. FDA panels are mainly comprised of practicing physicians from leading universities and hospitals. BMO Capital Markets analyst Jim Birchenough said he expects "panel members to be more constructive toward the carfilzomib data package." Birchenough recommended buying the stock, in a note to investors. Shares of Onyx Pharmaceuticals Inc., based in San Francisco, fell $1.90 to close at $44.08 Monday after rising as high as $46.99 earlier in the session. They are near their 52-week high of $47.80 in late April. Onyx has … Continue reading →

Posted in Drug Side Effects | Comments Off on Hometownstations.com-WLIO- Lima, OH News Weather SportsFDA focuses on toxic side effects with Onyx drug

FDA Focuses on Side Effects with Onyx Drug

Posted: Published on June 19th, 2012

The toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh its benefits for patients with a type of blood cancer, federal health regulators said Monday. The Food and Drug Administration warned that patients in a company study of the drug had a high rate of heart and lung side effects, some of which were fatal. The FDA posted its review of carfilzomib online ahead of a meeting Wednesday, where its panel of cancer experts will recommend whether the drug should be approved. Despite the negative tone of the review, some analysts said they expect the FDA's panel of outside experts to take a more favorable view. FDA panels are mainly comprised of practicing physicians from leading universities and hospitals. BMO Capital Markets analyst Jim Birchenough said he expects "panel members to be more constructive toward the carfilzomib data package." Birchenough recommended buying the stock, in a note to investors. Shares of Onyx Pharmaceuticals Inc., based in San Francisco, fell $1.90 to close at $44.08 Monday after rising as high as $46.99 earlier in the session. They are near their 52-week high of $47.80 in late April. Onyx has asked the FDA to approve carfilzomib as a … Continue reading →

Posted in Drug Side Effects | Comments Off on FDA Focuses on Side Effects with Onyx Drug

FDA focuses on toxic side effects with Onyx drug

Posted: Published on June 19th, 2012

WASHINGTON (AP) -- The toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh its benefits for patients with a type of blood cancer, federal health regulators said Monday. The Food and Drug Administration warned that patients in a company study of the drug had a high rate of heart and lung side effects, some which were fatal. The FDA posted its review of carfilzomib online ahead of a meeting Wednesday, where its panel of cancer experts will recommend whether the drug should be approved. Despite the negative tone of the review, some analysts said they expect the FDA's panel of outside experts to take a more favorable view. FDA panels are mainly comprised of practicing physicians from leading universities and hospitals. BMO Capital Markets analyst Jim Birchenough said he expects "panel members to be more constructive toward the carfilzomib data package." Birchenough recommended buying the stock, in a note to investors. Shares of Onyx Pharmaceuticals Inc., based in San Francisco, fell $1.90 to close at $44.08 Monday after rising as high as $46.99 earlier in the session. They are near their 52-week high of $47.80 in late April. Onyx has asked the FDA to approve carfilzomib … Continue reading →

Posted in Drug Side Effects | Comments Off on FDA focuses on toxic side effects with Onyx drug

Page 6,723«..1020..6,7226,7236,7246,725..6,7306,740..»